[Current value of positron emission tomography for prostate cancer follow-up].
Positron emission tomography (PET) is a non-invasive nuclear medicine technology which uses radiotracers and cameras slightly different from the ones used in other nuclear medicine tests. Most current indications are for oncological diseases; in nephrology-urology its use has been reduced because of the characteristics of the most commonly used radiotracer, 18F-fluor deoxiglucose (18F-FDG, a glucose analogue), which is excreted by the kidney, limiting the interpretation of the study in urologic malignancies. Currently, 18F-choline is a promising radiotracer for both staging and restaging, especially if hybrid PET/CT scan devices are used. New radiotracers will be needed in the evolution of PET to obtain information about more specific aspects of prostate carcinoma that will modify therapy and follow-up.
Sánchez-Salmón
Aida
A
Servicio de Medicina Nuclear, Complejo Hospitalario Universitario, Santiago de Compostela, España. aida.sanchez.salmon@sergas.es
Ruibal
Alvaro
A
D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography / Q000639:trends; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18